From ideas...to medical applications
In the absence of any straightforward laboratory tests, the most severe complication, known as type II heparin-induced thrombocytopenia (HIT) has...
From ideas...to medical applications
Midway between plasma haemostasis and cellular haemostasis are microparticles, rich in procoagulant phospholipids. An increase in this procoagulant...
From ideas...to medical applications
Listening to and exchanging ideas with members of the biomedical science community has enabled Stago to develop its expertise in the search for...
From ideas...to medical applications
Achieving a balanced policy with regard to investment in research & development (R&D), technological monitoring and rational acquisitions is a key...
June 29th - July 4th, 2013
July 28 - August 1, 2013
December 7 - 10, 2013
This 
free educational application in English is the first of its kind and has been developed by an expert in Haemostasis… Stago.
STA®-Liatest® FM, the new marker for DIC
To better diagnose DIC and for a reliable vital prognosis, Stago has developed STA®-Liatest® FM, a new quantitative and fully-automated assay for fibrin monomers determination.
Heparin was discovered independently in 1911 by Doyon and in 1916 by McLean, for different reasons. The effect of heparin on blood clotting, however, had been observed one-third of a century earlier.
